Increased urinary concentrations of neoptcrin, an indicator of systemic immune activation, have been reported only in a minority of patients with breast cancer. We determined urinary neopterin by high-performance liquid chromatography in 78 patients with breast carcinoma, including 51 patients treated by systemic administration of doxorubicin and paclitaxel. Urinary neopterin before the therapy was not statistically different in patients compared to controls. Increased neopterin concentrations were more frequent in patients with advanced disease. A statistically significant increase in urinary neopterin, gradual decrease in hemoglobin and an increase in platelet counts were observed during doxorubicin/paclitaxel chemotherapy. The concentration of urinary neopterin before the second cycle of chemotherapy has shown significant negative correlation with the concentrations of hemoglobin later in the course of chemotherapy and a positive corrélation with platelet counts. In conclusion, urinary neopterin is normal in most patients with breast cancer. Increased urinary neopterin concentrations during doxorubicin/paclitaxel chemotherapy indicate the presence of systemic immune activation that seems to be associated with chemotherapy-induced anemia and thrombocytosis.
Introduction
Breast cancer is the most common malignant disease of women in the Western world ( 1 ) . The progress accomplished in the treatment of breast cancer over the last decades is now reflected in improved survival. In addition to early diagnosis, there is now strong evidence that much of the improvement of prognosis of women with breast cancer is the result of systemic therapy, including hormonal treatments and chemotherapy
(2).
It is now well established that malignant tumors elicit host response mediated by both adaptive and innate immune systems. The activation of the host immune system in patients with malignant tumors is often accompanied by markedly increased production of pteridines, e.g. neopterin. Neopterin is an unconjugated pteridine synthesized from guanosine triphosphate (GTP). GTP is converted to 7,8-dihydroneopterin by the enzyme guanosine triphosphate cyclohydrolase I (GTP cyclohydrolase I), and this reaction represents the first step in a pathway leading to the formation of tetrahydrobiopterin (3) . GTP cyclohydrolase I is the rate limiting enzyme in this pathway, and its activity is induced by interferon-γ (IFN-γ) (4), produced by Tlymphocytes and natural killer (NK) cells. Human macrophages possess significant GTP cyclohydrolase I activity when stimulated by IFN-γ, while the activity of other enzymes of this pathway is low (5) , leading to the accumulation of 7,8-dihydroneopterin which undergoes autooxidation to neopterin. The ratio of 7,8-dihydroncoptcrin to neopterin is constant (6) , and therefore neopterin concentrations are used to assess in vivo macrophage activation and. because neopterin production is the result of activation by IFN-γ, systemic immune activation. An increase in serum or urinary Correspondence to: Bohuslav Melichar M.D., Ph.D., Klinika onkologie a radioterapie, Lekarska fakulta Univerzity Karlovy a Fakultni nemocnice, Budova 23, Sokolska 581, 500 05 Hradcc Kralovc, Czcch Republic. Tel +420-49-5834574; fax +420-49-5832081 ; e-mail: melichar@fnhk.cz ncopterin concentrations in cancer patients has been amply documented (7, 8) . High neopterin concentrations have been observed in patients with tumor presenting mostly in advanced stage, e.g. lymphoma (9) , while neopterin concentrations similar to normal levels have been reported in tumors usually presenting in an early stage, e.g. breast carcinoma (10) . Advanced cancer is often accompanied by anemia that may be further aggravated by antitumor therapy ( 11 ) . In the majority of cancer patients, anemia may be categorized as anemia of chronic disease, characterized by low serum iron, low serum iron binding capacity and high ferritin (12) . The decline of hemoglobin concentrations in anemia of chronic disease results from the alterations of iron metabolism associated with acute phase response and direct inhibition of hematopoietic progenitors by cytokines responsible for systcmic inflammatory and immune response, e.g. I FN-γ, (12) , and the decline in hemoglobin levels is associated with increased neopterin concentrations. A negative correlation between serum neopterin concentrations and hemoglobin has been observed in patients with hematological and gynecological malignancies (13, 14) .
In the present study, we have investigated urinary ncopterin in patients with breast carcinoma. In addition, urinary neopterin, hemoglobin and peripheral blood cell count were followed in patients treated by doxorubicin/paclitaxel combination chemotherapy.
Material and Methods
Seventy-eight female patients, aged 59 ± 11 (range 38 -93) years with histologically confirmed diagnosis of breast carcinoma treated in the Department of Oncology and Radiotherapy, Charles University Medical School Teaching Hospital, Hradec Králové, Czech Republic, were evaluated in the present study. A sample of urine was obtained from the patients before the start of therapy. Eighteen healthy females, aged 51 ± 9 (range 39 -75) years, not suffering from any condition associated with systemic immune activation were included as controls. The urine samples were collected as part of a project approved by the institutional ethical committee. Peripheral blood cell count was performed as a part of routine evaluation before the administration of chemotherapy.
In 51 patients treated by the combination of doxorubicin and paclitaxel (25 patients with stage II, 22 patients with stage III, and 4 patients with stage IV or recurrent breast carcinoma), samples of urine and peripheral blood cell count were obtained before the start of each chemotherapy cycle. This regimen consisted of administration of doxorubicin (50 mg/m 2 ) and paclitaxel (175 mg/m : ) every 3 weeks. Premedication before each cycle included granisetron 3 mg intravenous bolus and dexametasone 1 6 mg in a short infusion. Three to 6 cycles of doxorubicin/paclitaxel combination were administered in the neoadjuvant or palliative setting in these 51 patients.
Samples of urine and peripheral blood were obtained before the administration of chemotherapy in the morning hours. Peripheral blood cell count was performed immediately, and morning urine specimens were collected and stored at -20°C until analysis that was performed within 3 months of sample collection. Urinary neopterin was measured by high-performance liquid chromatography. Briefly, after centrifugation (5 min, 1300 χ g) and diluting 100 μΐ of urine specimens with 1,0 ml of mobile phase containing 2 g of disodium-EDTA per liter, a 20 μΐ sample was injected onto a column. Neopterin was determined by reversed-phase using high performance liquid chromatography system LC1084A*Hewlett-Packard, Palo Alto, USA) with HP 79850 A integrator (Hewlett-Packard). Potassium phosphate buffer (15 mmol/1, pH 6,4) at flow rate of 0,8 ml/min was used as mobile phase. Neopterin was identified by its native fluorescence (353 nm excitation, 438 nm emission) by MPF-3 detector (PerkinElmer. Norwalk, USA) and quantified by external standard method. Creatinine was determined by Jaffc reaction after dilution of sample 1:50 (v/v) on a Hitachi 716 analyser (Tokyo, Japan) with commercial kit (Boehringer, Mannheim, Germany) according the manufacturer's instructions, and neopterin concentrations were expressed as neopterin/creatinine ratio (μπιοΐ/ιτιοί creatinine) as described earlier (15) . Peripheral blood cell count was performed as described (16) . Hemoglobin was measured by a photometric method using sodium lauryl sulfate, leukocytes were detected by flow cytometry and platelets by impedance method using a Sysmex XE-2100 blood analyzer (Sysmex, Kobe, Japan).
Urinary neopterin concentrations of patients and controls were compared by Mann-Whitney U test, Kruskal-Wallis test was used for comparison of neopterin in patients with different stage of the disease, neopterin before and during the treatment was compared by Wilcoxon signed rank test, and correlations between urinary neopterin and hematological parameters were investigated by Spearman's rank correlation. Fisher exact test was used to compare the frequency of patients with increased urinary neopterin. The decision on statistical significance was based on ρ = 0.05 level. The analyses were performed using NCSS 2001 software (Number Cruncher Statistical Systems, Kaysville, Utah, USA). 
Results
Urinary neopterin was increased only in a minority of patients with breast cancer and was not significantly different from controls. Values above 205 μιηοΐ/mol creatinine (mean + 2 standard deviations of controls) were observed only in 13 (17 %) patients. The mean urinary neopterin was not different in patients based on disease stage (Table 1 ) , but the frequency of increased neopterin (>205 μιποΐ/ιηοΐ creatinine) was significantly higher in patients with advanced disease (stage III. In 51 patients treated with doxorubicin/paclitaxel combination, urinary neopterin was followed before the start of the therapy and subsequent cycles. After treatment, a trend of moderate increase of urinary neopterin was observed that has reached statistical significance before cycles 4, 5 and 6 ( Figure 1) . Peripheral blood hemoglobin concentrations, leukocyte and platelet counts were within the normal range before the start of therapy. These parameters were ι; ϋ. 01?) (0.14! evaluated during treatment in 48 patients (excluding one patient who has received transfusion and 2 patients who had prior chemotherapy). A gradual statistically significant decrease in hemoglobin concentrations was observed during chemotherapy. Peripheral blood platelets increased markedly, compared to pretreatment values, 3 weeks after the first dose and before subsequent cycles. Peripheral blood leukocyte count was significantly increased before the cycles 2 and 3, but not before subsequent cycles ( Table 2 ). The declining number of measurements on each visit is due to different number of cycles administered (3 -6), and, only to a lesser extent, to missing measurements.
No correlation was observed between urinary neopterin, and peripheral blood hemoglobin, leukocytes and platelets before the treatment. However, uri- nary neopterin before the second cycle showed a strong statistically significant negative correlation with hemoglobin levels before the subsequent cycles as well as a weaker correlation with baseline hemoglobin concentrations (Table 3 ). In addition, a weak negative correlation of borderline significance was observed between pretreatment neopterin and hemoglobin concentrations before the cycles 5 and 6. Urinary neopterin before the second cycle also correlated significantly with the platelet count before the cycles 2, 3 and 5 (Table 4) . Correlations were also observed between neopterin concentrations before cycle 5 and platelets before cycles 3 and 4, and neopterin before cycle 6 and platelets before cycle 3. Urinary neopterin concentrations at different points have also shown statistically significant correlations (Table 5) . No correlations were observed between urinary neopterin and peripheral blood leukocyte counts. 
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Discussion
In agreement with an earlier report (10), we found increased urinary neopterin only in a minority of patients with breast cancer. Urinary neopterin is elevated in less than 20 % of patients at diagnosis, 1 7 % of patients in the present study and 1 8 % of patients in the study of Murr et al. (10) . Elevated neopterin levels have been associated with higher grade or metastatic disease (10) . Similarly, in the present study we have also found higher frequency of increased urinary neopterin in patients with advanced disease. The literature on neopterin as a marker of systemic immune activation in patients with breast cancer is limited. Increased urinary neopterin concentration was a significant prognostic factor in both univariate and multivariate analysis ( 10) . Slightly elevated serum neopterin concentrations have been observed in breast cancer survivors with chronic fatigue (17) .
The combination of doxorubicin and paclitaxel represents an effective regimen of cytotoxic chemotherapy both in the palliative as well as in neoadjuvant setting (18, 19) . Urinary neopterin increased moderately, but significantly during the therapy with this combination. Because neopterin was assessed only before the chemotherapy cycles, it is possible, that the magnitude of this increase is underestimated by the present data, as peak neopterin concentrations might have occurred before the administration of the subsequent cycle in 3 weeks. Marked increase in neopterin concentrations has been previously reported in patients with different malignancies after therapeutic administration of cytokines (7), but there is so far little information on the effect of chemotherapy on neopterin production (20) . In experimental studies, paclitaxel has been shown to induce macrophage activation (21, 22) . Present data also indicate that systemic immune activation, assessed by urinary neopterin, is associated with the decline of hemoglobin and thrombocytosis in breast cancer patients treated by doxorubicin/paclitaxel combination chemotherapy. Urinary neopterin measured 3 weeks after the first cycle of chemotherapy showed negative correlation with concentrations of hemoglobin and positive correlation with platelet counts later during the therapy. This correlation may be explained by a time lag between stimulus and subsequent changes in hematopoiesis that develop gradually over time. Interestingly, hemoglobin concentrations and platelet counts occasionally showed correlations with subsequent urinary neopterin levels. Patients with systemic immune or inflammatory activation, evidenced by low hemoglobin, thrombocytosis or high urinary neopterin concentrations, may exhibit an increased susceptibility for further activation, as suggested with the correlations of hemoglobin concentrations and platelet counts with subsequent urinary neopterin as well urinary neopterin concentrations on subsequent occasions. Obviously, the present analysis is retrospective, multiple correlations were performed, and it might be argued that some of these correlations were spurious. On the other hand, these correlations are consistent (inverse correlations with hemoglobin concentrations and positive correlations with platelet counts) and have been observed on multiple occasions.
Chemotherapy-induced anemia is well documented in patients with breast cancer (11) . The negative correlation between neopterin and hemoglobin may be explained by simultaneous action of cytokines, e.g. IFN-γ, on both erythropoiesis and neopterin production (12) (13) (14) . In addition, pteridines, e.g. tetrahydrobiopterin, may affect erythropoiesis directly. 7,8-dihydroneopterin reduces ferric to ferrous iron, facilitating the transfer of iron to depository forms (23) . Along with some other cytotoxic drugs, paclitaxel has been shown to activate macrophages (21, 24) . Systemic immune and inflammatory activation causes a decline in scrum iron and iron binding capacity, and simultaneous increase in depository iron (ferritin) leading to a decrease in hemoglobin concentrations. Myelosuppression is thought to represent the principal mechanism responsible for chemotherapy-induced anemia. The negative correlation between the neopterin concentrations after the start of therapy and subsequent hemoglobin levels observed in the present study indicates that the systemic immune activation reflected in increased neopterin production may also be involved in the pathogenesis of chemothcrapy-induccd anemia. In addition, the chemotherapy regimen used in the present cohort of patients had differential effect on hemoglobin and peripheral blood platelet counts, further supporting the hypothesis that myelosuppression is not the only mechanism responsible for chcmotherapy-induced anemia.
The thrombocytosis induced by the administration of doxorubicin/paclitaxel combination is analogous to platelet-sparing effect of paclitaxel that has been documented in patients treated by the combination of paclitaxel and carboplatin (25) (26) (27) . It has been previously demonstrated that thrombopoietin is responsible for platelet-sparing effect of paclitaxel (28) . Little is known about the platelet-sparing effect of paclitaxel in combination with other cytotoxic agents. The data presented here demonstrate that in patients treated with the combination of doxorubicin and paclitaxel the platelet-sparing effect goes beyond mere compensation of chemotherapy-induced decrease in platelets count, and a marked increase of peripheral blood platelet counts was observed. Systemic inflammatory Pteridines/ΎοΙ. 1 7ANo. 4 activity is associated with thrombocytosis, and cytokines, e.g. interleukin-6, are involved in thrombopoiesis. The thrombopoietic activity of interleukin-6 is mediated by thrombopoietin (29) . In cancer patients, interleukin-6 administration has been demonstrated to lead to thrombocytosis and increased neopterin concentrations (30) . A positive correlation observed between urinary neopterin concentrations before cycle 2 and subsequent platelet counts indicates that, similarly to chemotherapy-induced anemia, systemic immune activation may be involved in the pathogenesis of this phenomenon.
Further studies should address the question about the impact of chemotherapy-induced thrombocytosis on the therapeutic outcome. It has not only been demonstrated that platelets can destroy cancer cell in vitro (31) , but, on the other hand, platelets contain molecules that are critical for tumor growth or progression, e.g. platelet-derived growth factor or vascular endothelial growth factor that represent potent inducers of angiogenesis (32) . Chemotherapy-induced thrombocytosis may thus both potentiate the antitumor effect of cytotoxic drugs or foster tumor growth.
In conclusion, in agreement with previous reports, urinary neopterin was increased before the start of therapy only in a minority of patients. A moderate, but significant increase was observed during the chemotherapy with combination of doxorubicin and paclitaxel. Chemotherapy-induced anemia and thrombocytosis correlated with increased urinary neopterin concentrations. These results open the possibility that systemic immune activation may be involved in the pathogenesis of chcmotherapy-induced anemia and thrombocytosis associated with doxorubicin/paclitaxel chemotherapy.
